Mankind Pharma Limited has entered into an exclusive in-licensing and marketing agreement with China’s Chongqing Chenan Biopharmaceutical for two insulin analogues: Insulin Degludec and Insulin Degludec + Aspart Combination. This strategic move aims to bolster Mankind Pharma’s presence in the diabetes care segment and expand its injectable diabetes portfolio in India. The partnership underscores the company’s commitment to making advanced therapies accessible to Indian patients.
Mankind Pharma Forges Strategic Partnership for Diabetes Care
New Delhi, August 20, 2026 – Mankind Pharma Limited, a prominent Indian pharmaceutical company, has announced a significant in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical Co., Ltd., based in China. This exclusive deal grants Mankind Pharma the rights to commercialize two critical insulin analogues in the Indian market: Insulin Degludec and Insulin Degludec + Aspart Combination.
Expanding Diabetes Portfolio and Market Reach
This strategic partnership represents a key step in Mankind Pharma’s ongoing strategy to strengthen its position in the rapidly growing diabetes care sector. The inclusion of these advanced injectable therapies is expected to significantly enhance the company’s existing portfolio, catering to the evolving needs of patients requiring sophisticated diabetes management solutions. The agreement reinforces Mankind Pharma’s commitment to broadening its range of treatment options available to the Indian populace.
Leveraging Global Innovation for India
Atish Majumdar, Senior President – Sales and Marketing at Mankind Pharma Ltd., commented on the development, highlighting China’s emergence as a hub for biopharmaceutical innovation. “Building on our partnerships for Insulin Aspart and Insulin Degludec, we remain focused on expanding our in-licensing pipeline from China. This partnership reinforces our commitment to expanding access to advanced therapies for patients in India while further strengthening our presence in the injectable diabetes segment,” he stated. The collaboration aligns with Mankind Pharma’s broader strategy of leveraging global innovations through strategic partnerships.
About Mankind Pharma Limited
Mankind Pharma is recognized as one of India’s largest pharmaceutical companies, with a strong focus on the domestic market and a Pan India presence. The company operates across acute and chronic therapeutic areas, including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, gynaecology, VMN, and respiratory segments. Its consumer healthcare business also covers a wide array of products, including condoms, pregnancy detection, and supplements. With 32 manufacturing facilities and a robust distribution network, Mankind Pharma is dedicated to providing quality and affordable healthcare solutions.
Source: BSE
